Loading
Day One Biopharmaceuticals, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 20 Oct 2023.
Day One Biopharmaceuticals, Inc.: what insiders have been doing
Day One Biopharmaceuticals, Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). 9 insiders have disclosed 25 filings since 18 October 2025.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
For context, the typical company on the same exchange (median of 5,808 companies) published 19 filings over the same period, against 25 filings here. Over the whole record (from 2021), the tally stands at 7 purchases and 67 sales. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 158.2 m USD and net income at -107.32 bn USD.
Over the last twelve months, not one insider purchase of Day One Biopharmaceuticals, Inc. stock was filed. Typically, a trade is published a median of 3 days after it takes place. For comparison, the SEC allows two business days to file a Form 4.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Cytosorbents Corp. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
164
Thresholds
n/a
Buy Volume
€47M
7 ops. · all time
Sell Volume
€32M
67 ops. · all time
Who traded when
BuySaleSamuel C. Blackman3 sales
Since the insiders bought
- -32.8%Entry US$17.78 · Close at T+365 US$11.94
- -30.1%Entry US$17.78 · Close at T+365 US$12.43
- -63.1%Entry US$19.01 · Close at T+365 US$7.02
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 19,099 of 24,148 companies
31.6
score / 100
Value15
Quality48
FCF yld-11%
Earn yld-11%
EV/EBITDA·
ROE·
Gross mgn89%
Net mgn-68%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$21.53
Income statement
RevenueUS$158.2M
Gross profitUS$141M89% margin
Net income-US$107.3M-67.8% margin
Balance sheet & cash
Market capUS$956.9M
Total debtUS$2.8M
Free Cash Flow-US$107.6M
Last declaration on 27 April 2026
Declarations164 total
12,929,322 shares@ US$21.5028.35% mcap86.7% of flowCommon StockSEC:0001193125-26-182440:0
204,643 sharesCommon StockSEC:0001863107-26-000005:0
20,204 sharesCommon StockSEC:0001863107-26-000005:1
300,000 sharesCommon StockSEC:0001863107-26-000005:2
147,702 sharesCommon StockSEC:0001863107-26-000005:3
18,197 sharesCommon StockSEC:0001863107-26-000005:4
300,000 sharesCommon StockSEC:0001863107-26-000005:5
808,285 sharesCommon StockSEC:0001863107-26-000005:6
40,485 sharesCommon StockSEC:0001547959-26-000008:0
57,310 sharesCommon StockSEC:0001580111-26-000001:0
312,025 sharesCommon StockSEC:0001655962-26-000005:0
4,397 sharesCommon StockSEC:0001734755-26-000005:0
72,694 sharesCommon StockSEC:0001744507-26-000005:0
72,292 sharesCommon StockSEC:0001776351-26-000001:0
60,157 sharesCommon StockSEC:0001855298-26-000006:0
4,750 sharesCommon StockSEC:0001863107-26-000004:0
3,162 sharesCommon StockSEC:0001855298-26-000004:0
2,963 sharesCommon StockSEC:0001744507-26-000004:0
7,125 sharesCommon StockSEC:0001734755-26-000004:0
2,250 sharesCommon StockSEC:0001655962-26-000004:0
300,000 shares0Common StockSEC:0001863107-25-000007:0
1,375 sharesCommon StockSEC:0001655962-25-000006:0
3,570 sharesCommon StockSEC:0001863107-25-000005:0
3,162 sharesCommon StockSEC:0001855298-25-000007:0
2,963 sharesCommon StockSEC:0001744507-25-000006:0
25 of 164 declarations
About Day One Biopharmaceuticals, Inc.
Day One Biopharmaceuticals, Inc. is a U.S.-listed biopharmaceutical company trading on the NASDAQ market in the United States. The company was founded to address a long-standing unmet need in oncology, particularly the shortage of new, age-appropriate treatments for children with cancer. From an analyst’s perspective, Day One’s identity is that of a targeted oncology innovator that has moved from a development-stage profile toward commercial execution, with its corporate headquarters in Brisbane, California, in the San Francisco Bay Area. ([ir.dayonebio.com](https://ir.dayonebio.com/?utm_source=openai))
Its business model centers on the discovery, development, and commercialization of targeted therapies for patients of all ages with life-threatening diseases. The company’s lead commercial product is tovorafenib, sold as OJEMDA™, an oral, brain-penetrant, highly selective type II pan-RAF inhibitor. OJEMDA is aimed at pediatric, adolescent, and young adult patients with relapsed or progressive low-grade glioma, making it one of the company’s most important value drivers and the key asset behind Day One’s transition into a commercial-stage company. In parallel, the pipeline includes DAY301, and, following the acquisition of Mersana Therapeutics, Emi-Le (emiltatug ledadotin), an antibody-drug conjugate targeting B7-H4 and being developed for the rare cancer adenoid cystic carcinoma. ([ir.dayonebio.com](https://ir.dayonebio.com/news-releases/news-release-details/day-one-announces-closing-upsized-initial-public-offering-and?utm_source=openai))
Read moreShow less
From a competitive standpoint, Day One is positioned in highly specialized oncology niches rather than broad, crowded primary-care markets. That can be an advantage if clinical differentiation, regulatory exclusivity, and physician adoption are strong, but it also means the investment case is more dependent on a narrow set of programs and execution milestones. The company’s strategy is consistent with a “precision oncology” approach: focus on genetically defined cancers and rare diseases where unmet medical need is high and pricing power can be more defensible. For investors, the opportunity is balanced by the usual biotech risks, including clinical development uncertainty, regulatory outcomes, commercial uptake, manufacturing, and the complexity of integrating acquisitions. ([ir.dayonebio.com](https://ir.dayonebio.com/?utm_source=openai))
Geographically, Day One is primarily U.S.-centric, with operations, commercialization, and investor communications anchored in the United States. Recent major developments have been material: the company reported preliminary 2025 OJEMDA net product revenue of $155.4 million and guided 2026 U.S. net product revenue to $225 million–$250 million, while also completing the Mersana acquisition in early 2026 to expand its pipeline and add a clinical-stage ADC platform. For market participants, these events indicate that Day One is increasingly being evaluated not only as a clinical story, but as a growth-oriented oncology commercial platform with expanding optionality. ([ir.dayonebio.com](https://ir.dayonebio.com/news-releases/news-release-details/day-one-announces-preliminary-2025-ojemdatm-net-product-revenue/?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
